Remus Pharmaceuticals Ltd
Remus Pharmaceuticals Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Remus Pharmaceuticals expects sustainable growth in revenue in the coming years, avoiding exorbitant spikes seen earlier due to consolidation effects. Remus Pharmaceuticals anticipates sustainable growth in revenues and profits going forward, avoiding the exceptionally high growth seen due to previous consolidation effects.
From Remus Pharmaceuticals Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Remus Pharmaceuticals expects sustainable growth in revenue in the coming years, avoiding exorbitant spikes seen earlier due to consolidation effects.
- The company anticipates significant expansion in its B2C portfolio, aiming to increase B2C business share from 10-15% to 25-30% by the end of the current year, which should enhance gross margins.
- They plan to launch over 2,000 new B2C products in the coming years and currently have around 570 B2C SKUs, with filings ongoing to expand this further.
- New product registrations and market entries are underway in multiple countries like Bosnia, Kosovo, Mexico, Tanzania, Azerbaijan, Mauritius, Bhutan, and Cambodia.
- Latin America remains a key growth region with ongoing product launches and brand-building activities in countries like Chile, Peru, Dominican Republic, El Salvador, and Bolivia.
2 more points from Remus Pharmaceuticals Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Remus Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The transcript does not explicitly mention any specific current or future capex or capital investment plans.
- The company is focused on expanding its product portfolio and market presence through:
- Registration of new products in multiple countries.
- Developing branded generics portfolio, particularly in B2C markets.
- Opening a branch office in Singapore to enhance business feasibility and international operations.
- They are investing in R&D (~2-3% of turnover) for product registrations and development to support global expansion.
- Emphasis is on product filings and regulatory compliance rather than large fixed capital expenditures.
2 more points from Remus Pharmaceuticals Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Remus Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Remus Pharmaceuticals discussed filing around 250 B2C products and additional filings under B2B.
- The company anticipates substantial numbers from the filing perspective, aiming for a large pipeline of new products.
- Currently, there are about 570 B2C SKUs, with plans to reach around 2000 new B2C products in the near future.
- The product registration process is active across multiple new countries including Bosnia, Kosovo, Mexico, Tanzania, Azerbaijan, Mauritius, Bhutan, and Cambodia.
- The company is also working on new product launches in key Latin American markets and has recently launched over 15 products in Bolivia.
2 more points from Remus Pharmaceuticals Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
What Remus Pharma.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharma. (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Arthneeti Pro · Annual
Remus Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Remus Pharmaceuticals Ltd Q4 FY25 results?
Remus Pharmaceuticals expects sustainable growth in revenue in the coming years, avoiding exorbitant spikes seen earlier due to consolidation effects. Remus Pharmaceuticals anticipates sustainable growth in revenues and profits going forward, avoiding the exceptionally high growth seen due to previous consolidation effects.
What is Remus Pharmaceuticals Ltd share price analysis?
Remus Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 24.5 with a market cap of ₹906 Cr. Investors should review the full earnings analysis for detailed insights.
Is Remus Pharmaceuticals Ltd planning capital expenditure?
The transcript does not explicitly mention any specific current or future capex or capital investment plans.
Keep Remus Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.